1. Spain: unpublished regional data link nine deaths to metamizole agranulocytosis, seven in British residents
EL PAÍS reported on 16 November on a 2019 internal report from the Valencia regional government, presented at the congress of the Spanish Society of Hospital Pharmacy, which identified 41 patients hospitalised with metamizole-induced agranulocytosis in coastal areas of Alicante province in 2016–2017; 26 were British, and nine patients died, seven of them British and two Spanish. The report estimated 39.8 cases per 100,000 defined daily doses in UK-born residents versus 0.33 in Spaniards, roughly a 120-fold difference. The Spanish agency AEMPS replied that the study is descriptive, does not allow incidences or relative risks to be calculated and does not control for biases, and it maintains that the benefit-risk balance of metamizole remains positive; EMA's 2023–2024 review also concluded that benefits outweigh risks, with package leaflet changes to help detect complications. For safety teams, the case shows how unpublished regional analyses can resurface and reopen a known risk, and why nationality, residency and ancestry should be recorded in case reports when population-specific susceptibility is suspected. EL PAÍS, 16 Nov 2026
2. Psilocin analogue HLP003 meets its Phase 3 endpoint, with a suicide attempt among three treatment-related serious adverse events
Helus Pharma reported on 16 November that the Phase 3 APPROACH trial of HLP003, a deuterated psilocin analogue given as adjunctive treatment to 222 people with moderate-to-severe major depressive disorder, met its primary endpoint at six weeks. On an investor call the company disclosed three treatment-related serious adverse events: two cases of depression and one suicide attempt, in a non-responder, 55 days after the second dose; the company said most adverse events were mild to moderate, transient and mainly limited to the day of dosing. For safety teams working on psychedelic and other rapid-acting antidepressants, suicidality events that occur weeks after dosing, outside the acute monitoring window, need structured follow-up, careful causality assessment and transparent disclosure, as regulators and investors will scrutinise them. BioSpace, 16 Nov 2026
3. MHRA launches a programme to close evidence gaps on medicines and devices for women
On 16 November MHRA launched a Women's Health Programme aimed at better evidence on how the benefits and risks of medicines and medical devices may differ for women. An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 found that pregnant women were represented in just 1.1% of trials and breastfeeding women in 0.6%. The programme will bring together patients, researchers, healthcare professionals and industry, and MHRA will hold an introductory webinar on 9 December. For safety teams, it signals growing UK regulatory attention to pregnancy and lactation data, which in practice still depend heavily on post-marketing pregnancy exposure reports and registries. MHRA, 16 Nov 2026
4. US: one lot of propranolol extended-release capsules recalled over possible metal contamination
Breckenridge Pharmaceutical announced on 16 November a voluntary consumer-level recall of one lot (PK25110035) of propranolol hydrochloride extended-release capsules 60 mg, manufactured by Adare Pharma Solutions, which was distributed nationwide between 26 October and 4 November 2026. The affected lot shared intermediate material suspected to be the source of metal contamination found in a separate, unreleased lot; use could potentially cause lacerations of soft tissues in the mouth, oesophagus, stomach or intestine, and the company says it is not aware of any related adverse events. For safety and quality teams, the recall shows why a defect found in an unreleased batch should trigger a trace of shared intermediates, and why reports of gastrointestinal bleeding or injury linked to the affected lot should be followed up. Breckenridge Pharmaceutical, 16 Nov 2026
This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.
Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles